Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Amneal Pharmaceuticals, a US-based company that manufactures, develops and distributes generic pharmaceuticals regulated and approved by the FDA, has appointed Shankar Hariharan as chief scientific officer (CSO) and executive vice president (EVP) of specialty pharmaceuticals.
Subscribe to our email newsletter
Prior to joining Amneal Pharma Dr Hariharan worked as CSO and EVP of Par Pharmaceutical.
Additionally, he built internal expertise in abbreviated new drug applications (ANDAs) for generics and redirected the product selection strategy to value-added offerings such as sustained release and modified release drugs.
Recently, Dr Hariharan worked for DermAct Pharmaceutical, Melville, NY and Action Medicines of Spain as CEO and co-founder. He has also held senior executive and R&D management positions with Forest Laboratories, Inwood, NY and IDR Laboratory and Clinic, in Rockville, MD.
Chintu Patel, CEO and co-founder of Amneal Pharma, said: “Dr Shankar Hariharan’s depth of R&D experience, proven results and leadership skills bring value to Amneal as we extend our reach in both generic and specialty pharmaceuticals.”
Dr Hariharan said: “I look forward to applying my experience to support Amneal’s R&D expansion into specialty pharma and further enhance our product portfolio. Amneal has an outstanding reputation in the generics industry, and I’m very pleased to facilitate their continued growth.”